Clinical impact of early response to first‐line VEGFR‐TKI in patients with metastatic renal cell carcinoma on survival: A multi‐institutional retrospective study

Clinical impact of early response to first‐line VEGFR‐TKI in patients with metastatic renal cell carcinoma on survival: A multi‐institutional retrospective study

Abstract It remains unknown whether the early response to vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR‐TKI) management in malignancies links to long‐term survival. The objective of this study was to investigate the survival rates and predictive factors of early respon...

Full description

Bibliographic Details
Main Authors: Ryuta Sobu, Kazuyuki Numakura, Sei Naito, Shingo Hatakeyama, Renpei Kato, Tomoyuki Koguchi, Takahiro Kojima, Yoshihide Kawasaki, Syuya Kandori, Sadafumi Kawamura, Yoichi Arai, Akihiro Ito, Hiroyuki Nishiyama, Yoshiyuki Kojima, Wataru Obara, Chikara Ohyama, Norihiko Tsuchiya, Tomonori Habuchi
Format: Article
Language:English
Published: Wiley 2023-02-01
Series:Cancer Medicine
Subjects:
axitinib
early response
metastatic renal cell carcinoma
VEGFR‐TKI
Online Access:https://doi.org/10.1002/cam4.5268

Internet

https://doi.org/10.1002/cam4.5268

Similar Items